Search results for "pancreatic cancer pain"

showing 2 items of 2 documents

Celiac plexus block for pancreatic cancer pain: Factors influencing pain, symptoms and quality of life

2003

Neurolytic celiac plexus block (NCPB) is claimed to be an effective method of pain control for pancreatic cancer pain. However, the factors that may influence long-term analgesia, adverse effects, and quality of life after performing NCPB have never been determined. In a prospective multicenter study, 22 patients who underwent NCPB were followed until death. Numerous parameters other than pain and symptom intensity were evaluated, including age, gender, initial site of cancer, sites of pain, possible peritoneal involvement, technique, and oncologic interventions. Indices were calculated to determine the opioid consumption ratio (EAS) and the trend of opioid escalation (OEI). NCPB was effect…

MalePalliative caremedicine.medical_treatmentPopulationAnalgesicCeliac plexusPainCeliac PlexusOpioidCancer epidemiologymedicineHumansProspective StudieseducationProspective cohort studyNeurolytic celiac plexus blockGeneral NursingNeurolysisNursing (all)2901 Nursing (miscellaneous)education.field_of_studybusiness.industryNerve BlockMiddle AgedAnalgesics OpioidPancreatic Neoplasmsmedicine.anatomical_structureAnesthesiology and Pain MedicineOpioidAnesthesiaQuality of LifeNerve blockPancreatic cancer painFemaleNeurology (clinical)businessmedicine.drug
researchProduct

Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study.

2010

Objective: According to experimental findings, oxycodone (OX) could have some advantages over morphine (MO) in clinical models of visceral pain. It was hypothesized that OX could have some advantages over MO in terms of efficacy and dose escalation in pancreatic cancer pain. Methods: Sixty patients with pancreatic cancer with a pain intensity rating of 4/10 who required opioids were included in the study. Patients were randomized to receive 30mg/d of sustained release oral MO or sustained release oral OX (20mg/d). Opioid doses were increased according to the clinical needs. Daily doses of opioids, pain and symptom intensity were recorded at admission (T0) and at weekly intervals for the sub…

AdultMalePancreatic diseaseSettore MED/06 - Oncologia MedicaPopulationPainmorphine; opioids; oxycodone; pancreatic cancer pain; visceral painStatistics Nonparametricpancreatic cancer painPancreatic cancermedicineHumanseducationPain Measurementeducation.field_of_studyMorphinebusiness.industryVisceral painmedicine.diseaseAnalgesics OpioidPancreatic NeoplasmsAnesthesiology and Pain MedicineTreatment OutcomeOpioidAnesthesiaopioidMorphineFemalevisceral painNeurology (clinical)medicine.symptomAnalgesiaCancer painbusinessOxycodoneOxycodonemedicine.drugThe Clinical journal of pain
researchProduct